Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Eli Lilly (NYSE:LLY) has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025. The company will be represented by Jacob Van Naarden, executive vice president and president of Lilly Oncology, and David Hyman, M.D., Lilly chief medical officer, who will participate in a fireside chat at 9:15 a.m. ET.
Investors can access a live audio webcast of the presentation through Lilly's investor website, with a replay available for approximately 90 days following the event.
Eli Lilly (NYSE:LLY) annuncia la sua partecipazione al Morgan Stanley 23rd Annual Global Healthcare Conference che si terr脿 l'8 settembre 2025. L'azienda sar脿 rappresentata da Jacob Van Naarden, executive vice president e presidente di Lilly Oncology, e da David Hyman, M.D., chief medical officer di Lilly, che interverranno in un fireside chat alle 9:15 ET.
Gli investitori potranno ascoltare la presentazione in diretta tramite webcast audio sul sito investor di Lilly; la registrazione rester脿 disponibile per la visione per circa 90 giorni dopo l'evento.
Eli Lilly (NYSE:LLY) ha anunciado su participaci贸n en la Morgan Stanley 23rd Annual Global Healthcare Conference el 8 de septiembre de 2025. La compa帽铆a estar谩 representada por Jacob Van Naarden, vicepresidente ejecutivo y presidente de Lilly Oncology, y por David Hyman, M.D., director m茅dico de Lilly, quienes participar谩n en un fireside chat a las 9:15 a.m. ET.
Los inversores podr谩n acceder a la transmisi贸n de audio en directo a trav茅s del sitio web para inversores de Lilly; la reproducci贸n estar谩 disponible durante aproximadamente 90 d铆as tras el evento.
Eli Lilly (NYSE:LLY)電� 2025雲� 9鞗� 8鞚� 臧滌禍霅橂姅 Morgan Stanley 23rd Annual Global Healthcare Conference鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� Jacob Van Naarden (Lilly Oncology 雼措嫻 靾橃劃攵�靷灔 瓴� 靷灔)瓿� David Hyman, M.D. (Lilly 斓滉碃 鞚橂 毂呾瀯鞛�)臧� 雽�響滊 彀胳棳頃橂┌, 鞓れ爠 9:15(霃欕秬鞁滉皠)鞐� 歆勴枆霅橂姅 韺岇澊鞏挫偓鞚措摐 毂勴寘鞐� 彀胳劃頃╇媹雼�.
韴瀽鞛愲摛鞚� Lilly 韴瀽鞛� 鞗轨偓鞚错姼毳� 韱淀暣 頂勲爤鞝犿厡鞚挫厴鞚� 鞓る敂鞓� 霛检澊敫� 鞗轨簮鞀ろ姼鞐� 鞝戩啀頃� 靾� 鞛堨溂氅�, 頄夓偓臧� 雭濍倻 頉� 鞎� 90鞚缄皠 鞛箔旆皜 臧�電ロ暕雼堧嫟.
Eli Lilly (NYSE:LLY) a annonc茅 sa participation 脿 la Morgan Stanley 23rd Annual Global Healthcare Conference le 8 septembre 2025. La soci茅t茅 sera repr茅sent茅e par Jacob Van Naarden, vice-pr茅sident ex茅cutif et pr茅sident de Lilly Oncology, et par David Hyman, M.D., directeur m茅dical de Lilly, qui prendront part 脿 un fireside chat 脿 9h15 (ET).
Les investisseurs pourront suivre la pr茅sentation via un webcast audio en direct sur le site investisseurs de Lilly ; un replay sera disponible pendant environ 90 jours apr猫s l'茅v茅nement.
Eli Lilly (NYSE:LLY) hat seine Teilnahme an der Morgan Stanley 23rd Annual Global Healthcare Conference am 8. September 2025 angek眉ndigt. Das Unternehmen wird durch Jacob Van Naarden, Executive Vice President und Pr盲sident von Lilly Oncology, sowie David Hyman, M.D., Chief Medical Officer von Lilly, vertreten sein; beide nehmen um 9:15 Uhr ET an einem Fireside-Chat teil.
Investoren k枚nnen die Pr盲sentation per Live-Audio-Webcast 眉ber Lilys Investor-Webseite verfolgen; eine Aufzeichnung steht etwa 90 Tage nach der Veranstaltung zur Verf眉gung.
- None.
- None.
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
About Lilly
Lilly is a medicine company turning science into healing听to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit听 补苍诲听, or follow us on , , and . F-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the 庐 and 鈩� symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Refer to:听 听 听 | Ashley Hennessey; [email protected]; 317-416-4363 (Media) |
Michael Czapar; [email protected]; 317-617-0983 (Investors) |
听
听
View original content to download multimedia:
SOURCE Eli Lilly and Company
FAQ
When is Eli Lilly (LLY) presenting at the Morgan Stanley Healthcare Conference 2025?
Who will represent Eli Lilly at the Morgan Stanley Healthcare Conference 2025?
How can investors access Eli Lilly's Morgan Stanley conference presentation?
How long will the replay of Eli Lilly's Morgan Stanley conference presentation be available?
